PU23.03	Being a part of the conversation: capacitating youth to participate in HIV prevention conversations using a digital citizen engagement platform in South Africa	Publication Only	Policy and advocacy
PU21.08	Distinct classes of HIV-1 cross-clade neutralizing antibodies targeting fusion peptide elicited in mice by diverse immunization regimens	Publication Only	Novel vaccine and other prevention approaches
PU21.06	DNA vs ChAd-vectored vaccines as priming vaccines in heterologous prime-boost regimens to increase HTI immunogenicity in mice	Publication Only	Novel vaccine and other prevention approaches
PU21.03	Co-display of hyperstabilized HIV-1 envelope glycoprotein trimers on two-component protein nanoparticles	Publication Only	Novel vaccine and other prevention approaches
PU21.03	Assessment of crosslinker suitability for fusion peptide conjugates as priming immunogens for an HIV-1 vaccine	Publication Only	Novel vaccine and other prevention approaches
PU21.02	Comparison of HIV incidence in simulated vaccine efficacy trials and observational cohorts using propensity scores in key populations in Uganda	Publication Only	Novel vaccine and other prevention approaches
PU21.01	Willingness of adolescent girls and young women in Kampala, Uganda to participate in future efficacyttrials of novel biomedical HIV prevention interventions: the anti-retroviral implant	Publication Only	Novel vaccine and other prevention approaches
PU20.02	Asymptomatic bacterial STI in young men who have sex with men minimally alters rectal mucosal immune cell ecosystem	Publication Only	Mucosal immunity
PU20.01	Vaccination with Ad26.ZEBOV, MVA-BN-Filo or MVA-BN-Filo, Ad26.ZEBOV induced predominantly IgG binding to Ebola glycoprotein in cervico-vaginal mucus in HIV-infected and uninfected participants	Publication Only	Mucosal immunity
PU19.01	The impact of vaginal Lactobacillus isolates on host gene expression involved in inflammation in the female genital tract	Publication Only	Microbiome & STI: impact on prevention